Revolution Medicines’ daraxonrasib produced promising early anti-tumor effects in a Phase 1/2 trial in advanced pancreatic cancer, according to results published in the NEJM, with the study led by researchers at The University of Texas MD Anderson Cancer Center. The oral, multi-selective RAS inhibitor is designed to target RAS-driven disease biology. The report frames daraxonrasib as an actionable RAS approach after ongoing challenges with conventional RAS targeting strategies across solid tumors. As a Phase 1/2 readout, the focus is likely on safety, tolerability, and early efficacy signals in RAS-mutant cohorts. For the pancreatic cancer pipeline, the key will be whether responses deepen or stabilize with longer follow-up and which biomarkers correlate most strongly with benefit. Any confirmation of clinically meaningful activity would support expansion into larger cohorts or additional randomized studies. With pancreatic cancer remaining difficult to treat, early NEJM data can accelerate trial sequencing and partnership discussions across the category.